## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re A	Applicat	ion of:	Martin HENDRIX,	et al.				
Serial	No.: 10	)/586,501		Group Art Unit: 1624				
Filed:	Septem	nber 14, 20	007	Examiner: Rao Deepak R.				
For: (	For: CYANOPYRIMIDIONES							
INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98								
P.O. B	30x 1450	r for Paten () (A 22313-1						
and 1.9	This in 98 as fo		disclosure statement	is made in accordance with 37 C.F.R. §§ 1.56, 1.97				
<u>Timin</u>	g and Fe	<u>ees</u>						
$\boxtimes$		nder 37 C.F.R. § 1.97(b), no fee or statement is required for filing this information sclosure statement is filed:						
		within the		ng date of a national application other than a CPA				
		within th		ctual filing date of the national phase of a PCT				
	$\boxtimes$	before the RCE).	e mailing of a first su	bstantive office action (including after filing of an				
	Under 37 C.F.R. § 1.97(c), this information disclosure statement is filed after the perspecified in 37 C.F.R. § 1.97(b), but before the mailing date of:							
		termination		R. 1.113; g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR 7 C.F.R. § 1.311; and				

		is accompanied by:				
			the statement as specified in 37 C.F.R. § 1.97(e) set out below;			
			a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p); or			
			payment by credit card via EFS covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).			
			R. § 1.97(d), this information disclosure statement is filed after the mailing lowing actions which have not been withdrawn:			
a final act			action under 37 C.F.R. § 1.113;			
		termin	ation of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2);			
	OR a notice of allowance under 37 C.F.R. § 1.311;					
	AND i	s filed on or before payment of the issue fee; AND is accompanied by:				
	the statement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the f \$180.00 under 37 C.F.R. § 1.17(p).					
Staten	nents U	nder 37	C.F.R. 1.97(e)			
			Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or			
			No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.			
Cited	<u>Materia</u>	<u>ls</u>				
		Copies of materials listed but not attached were cited in benefit (35 U.S.C. § 120) ancestor application Serial No, on Form 892 by the Examiner and/or Form 1449 by the applicant; see 37 C.F.R. § 1.98(d).				
		Copies of materials listed, but not attached, were cited in an international report dated				

		Not required by 37 CFR § 1.98.				
	$\boxtimes$	Copies of the materials listed are attached (except for the foregoing).				
Non-En	ıglish I	Language References				
		An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).				
		A foreign-language search report from a foreign patent office is provided, a pertinent parts are translated substantively below:				
		<ul> <li>X = document of particular relevance when it is taken alone</li> <li>Y = document of particular relevance when it is combined with another such document</li> <li>A = document defining the general state of the art</li> <li>O = non-written disclosure</li> <li>P = intercalated document</li> <li>T = document cited to understand the theory or principle underlying the invention</li> <li>E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date</li> <li>D = cited in the application</li> <li>L = cited for another reason</li> <li>&amp; = publication of member of same patent family</li> <li>Translation of other relevant information on foreign search report</li> </ul>				
		[insert necessary translation here]				
Other In	<u>nforma</u>	<u>tion</u>				
		es Due (If Any):  ek for \$ covering the fee identified above is attached.				
	Payment by credit card via EFS for \$180.00 covering the fee identified above.					
	Please	charge to Deposit Account No. 13-3402 \$ for the fee identified above.				

The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402.

Respectfully submitted,

/John A. Sopp/

John A. Sopp, Reg. No. 33,103 Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C. Arlington Courthouse Plaza 1 2200 Clarendon Blvd. Suite 1400 Arlington, Virginia 22201 Telephone: (703) 243-6333

Facsimile: (703) 243-6410

Attorney Docket No.: 01-2118

Date: April 24, 2009